Sökning: WFRF:(Rotem Ofer) >
Real-world experien...
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP) : a retrospective analysis from an early access program
-
- Illini, Oliver (författare)
- Karl Landsteiner Inst Lung Res & Pulm Oncol, Austria
-
- Fabikan, Hannah (författare)
- Karl Landsteiner Inst Lung Res & Pulm Oncol, Austria
-
- Swalduz, Aurelie (författare)
- Claude Bernard Lyon 1 Univ, France; Univ Lyon, France; Univ Lyon, France
-
visa fler...
-
- Vikström, Anders (författare)
- Region Östergötland, Lungmedicinska kliniken US
-
- Krenbek, Dagmar (författare)
- Klin Floridsdorf, Austria
-
- Schumacher, Michael (författare)
- OKL Elisabethinen Linz, Austria
-
- Dudnik, Elizabeth (författare)
- Assuta Med Ctr, Israel
-
- Studnicka, Michael (författare)
- Paracelsus Med Univ, Austria
-
- Ohman, Ronny (författare)
- Univ Hosp Skane Lund, Sweden
-
- Wurm, Robert (författare)
- Med Univ Graz, Austria
-
- Wannesson, Luciano (författare)
- Ist Oncol Svizzera Italian, Switzerland
-
- Peled, Nir (författare)
- Shaare Zedek Med Ctr, Israel
-
- Kian, Waleed (författare)
- Shaare Zedek Med Ctr, Israel
-
- Bar, Jair (författare)
- Chaim Sheba Med Ctr, Israel; Tel Aviv Univ, Israel
-
- Daher, Sameh (författare)
- Canc Ctr Haim Sheba MC Tel, Israel
-
- Addeo, Alfredo (författare)
- Univ Hosp Geneva, Switzerland
-
- Rotem, Ofer (författare)
- Beilinson Med Ctr, Israel
-
- Pall, Georg (författare)
- Univ Hosp Innsbruck, Austria
-
- Zer, Alona (författare)
- Rambam Hlth Campus, Israel
-
- Saad, Akram (författare)
- Sheba Med Ctr, Israel; Tel Aviv Univ, Israel
-
- Cufer, Tanja (författare)
- Univ Clin Golnik, Slovenia; Univ Ljubljana, Slovenia
-
- Sorotsky, Hadas Gantz (författare)
- Canc Ctr Haim Sheba MC Tel, Israel
-
- Hashemi, Sayed M. S. (författare)
- Vrije Univ Amsterdam Med Ctr, Netherlands
-
- Mohorcic, Katja (författare)
- Univ Clin Golnik, Slovenia
-
- Stoff, Ronen (författare)
- Sheba Med Ctr, Israel
-
- Rovitsky, Yulia (författare)
- Carmel Hosp, Israel
-
- Keren-Rosenberg, Shoshana (författare)
- Carmel Hosp, Israel
-
- Winder, Thomas (författare)
- Acad Teaching Hosp Feldkirch, Austria; Univ Zurich, Switzerland
-
- Weinlinger, Christoph (författare)
- Karl Landsteiner Inst Lung Res & Pulm Oncol, Austria
-
- Valipour, Arschang (författare)
- Klin Floridsdorf, Austria; Karl Landsteiner Inst Lung Res & Pulm Oncol, Austria
-
- Hochmair, Maximilian J. (författare)
- Klin Floridsdorf, Austria; Karl Landsteiner Inst Lung Res & Pulm Oncol, Austria
-
visa färre...
-
(creator_code:org_t)
- 2022-06-13
- 2022
- Engelska.
-
Ingår i: Therapeutic Advances in Medical Oncology. - : Sage Publications. - 1758-8340 .- 1758-8359. ; 14
- Relaterad länk:
-
https://liu.diva-por... (primary) (Raw object)
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal-epithelial transition (MET) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which showed promising efficacy in this patient population in early trials. Methods: We performed a retrospective, international, multicenter efficacy and safety analysis in patients with NSCLC treated with capmatinib in an early access program between March 2019 and December 2021. Results: Data from 81 patients with advanced MET exon 14 mutated NSCLC treated with capmatinib in first- or later-line therapy were analyzed. Median age was 77 years (range, 48-91), 56% were women, 86% had stage IV disease, and 27% had brain metastases. For all patients, the objective response rate (ORR) to capmatinib was 58% (95% CI, 47-69), whereas it was 68% (95% CI, 50-82) in treatment-naive and 50% (95% CI, 35-65) in pretreated patients. The median progression-free survival was 9.5 months (95% CI, 4.7-14.3), whereas it was 10.6 months (95% CI, 5.5-15.7) in first-line and 9.1 months (95% CI, 3.1-15.1) in pretreated patients. After a median follow-up of 11.0 months, the median overall survival was 18.2 months (95% CI, 13.2-23.1). In patients with measurable brain metastases (n = 11), the intracranial ORR was 46% (95% CI, 17-77). Capmatinib showed a manageable safety profile. Grade > 3 treatment-related adverse events included peripheral edema (13%), elevated creatinine (4%), and elevated liver enzymes (3%). Conclusion: In patients with MET exon 14 skipping mutation, capmatinib showed durable systemic and intracranial efficacy and a manageable safety profile. This analysis confirms previously reported phase II data in a real-world setting.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kirurgi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Surgery (hsv//eng)
Nyckelord
- capmatinib; MET exon 14 skipping mutation; NSCLC; lung cancer; targeted therapy
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Illini, Oliver
-
Fabikan, Hannah
-
Swalduz, Aurelie
-
Vikström, Anders
-
Krenbek, Dagmar
-
Schumacher, Mich ...
-
visa fler...
-
Dudnik, Elizabet ...
-
Studnicka, Micha ...
-
Ohman, Ronny
-
Wurm, Robert
-
Wannesson, Lucia ...
-
Peled, Nir
-
Kian, Waleed
-
Bar, Jair
-
Daher, Sameh
-
Addeo, Alfredo
-
Rotem, Ofer
-
Pall, Georg
-
Zer, Alona
-
Saad, Akram
-
Cufer, Tanja
-
Sorotsky, Hadas ...
-
Hashemi, Sayed M ...
-
Mohorcic, Katja
-
Stoff, Ronen
-
Rovitsky, Yulia
-
Keren-Rosenberg, ...
-
Winder, Thomas
-
Weinlinger, Chri ...
-
Valipour, Arscha ...
-
Hochmair, Maximi ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kirurgi
- Artiklar i publikationen
-
Therapeutic Adva ...
- Av lärosätet
-
Linköpings universitet